Validation of the 2018 Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS) Guidelines for Preventing Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy

Masashi Amano; Hiroaki Kitaoka; Yusuke Yoshikawa; Toru Kubo; Yasushi Sakata; Kaoru Dohi; Yukichi Tokita; Takao Kato; Shouji Matsushima; Takeshi Kitai; Atsushi Okada; Yutaka Furukawa; Toshihiro Tamura; Akihiro Hayashida; Haruhiko Abe; Kenji Ando; Satoshi Yuda; Moriaki Inoko; Kazushige Kadota; Yuji Abe; K Iwakura; Tetsuya Kitamura; Jun Masuda; Takahiro Ohara; Takashi Omura; Takashi Tanigawa; Kenji Nakamura; Kunihiro Nishimura; Chisato Izumi

doi:10.1253/circj.cj-25-0765

Key Points

To validate the effectiveness of the 2018 JCS/JHFS guidelines for stratifying the risk of sudden cardiac death in hypertrophic cardiomyopathy patients.
Validation of the 2018 JCS/JHFS guidelines
Assessment of sudden cardiac death risk stratification
Focus on Class 2a recommendation for implantable cardioverter defibrillator
Guidelines exhibited good discriminatory performance for SCD risk stratification
Particularly effective among patients categorized with Class 2a recommendations

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Guidelines showed good performance in predicting sudden cardiac death risk in patients with hypertrophic cardiomyopathy, indicating effective risk stratification for treatment.

Abstract

The 2018 JCS/JHFS guidelines showed good discriminatory performance for SCD risk stratification, particularly among patients with Class 2a recommendations for an implantable cardioverter defibrillator.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Amano et al. (2025) studied this question.

synapsesocial.com/papers/69401d472d562116f28f8616 https://doi.org/10.1253/circj.cj-25-0765

View Full Paper

Ask AI

Bookmark

Share

Validation of the 2018 Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS) Guidelines for Preventing Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Validation of the 2018 Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS) Guidelines for Preventing Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading